Charles Elliott Sigal
CIK 1661908 · last filed 2026-05-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$81.44M
Companies
5
Total Filings
35
Lifetime Open-Market Net
$338.4K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| VIR | Director | 49,806 | $8.61 | $428.8K | $246.3K | 11 | 2026-05-28 |
| ALNY | Director | 3,446 | $282.85 | $974.7K | $0 | 5 | 2026-05-22 |
| Surface Oncology, Inc. (SURF) Delisted | Director | 0 | $1.07 | $0 | $0 | 9 | 2023-09-08 |
| Adaptimmune Therapeutics PLC (ADAP) Delisted | Director | — | $0.06 | — | $0 | 4 | 2023-07-03 |
| ASND | Director | 367,038 | $218.06 | $80.04M | $92.1K | 6 | 2019-07-03 |
Recent Filings · Page 4 of 4
35 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-04-23 | Surface Oncology, Inc. (SURF) Delisted | Conv (C) | +45,453 | $0 | EDGAR |
| 2017-07-03 | ASND | Grant (A) | — | $0 | EDGAR |
| 2016-08-12 | ASND | Grant (A) | — | $0 | EDGAR |
| 2016-05-19 | ASND | Buy (P) | +15,000 | $23.4K | EDGAR |
| 2016-05-18 | ASND | Buy (P) | +45,000 | $68.7K | EDGAR |
Showing 31–35 of 35
Prev
Page 4 of 4
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.